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Abstract 
Rationale: Lung cancer is the leading cause of cancer death worldwide, and treatment options are 
limited to mainly cytotoxic agents. Here we reveal a novel role of miR-150 in non-small cell lung 
cancer (NSCLC) development and seek potential new therapeutic targets.  
Methods: The miR-150-mediated autophagy dysfunction in NSCLC cells were examined using 
molecular methods in vitro and in vivo. The upstream regulatory element and downstream target of 
miR-150 were identified in vitro and validated in vivo. Potential therapeutic methods (anti-c-myc or 
anti-miR-150) were tested in vitro and in vivo. Clinical relevance of the c-myc/miR-150/EPG5 axis in 
NSCLC was validated in human clinical samples and large genomics database.  
Results: miR-150 blocked the fusion of autophagosomes and lysosomes through directly repressing 
EPG5. The miR-150-mediated autophagy defect induced ER stress and increased cellular ROS levels 
and DNA damage response, and promoted NSCLC cell proliferation and tumor growth. 
Knockdown of EPG5 promoted NSCLC cell proliferation, and attenuated the effects of miR-150. 
c-myc gene was identified as a miR-150 transcriptional factor which increased miR-150 
accumulation, therefore pharmacologically or genetically inhibiting c-myc/miR-150 expression 
significantly inhibited NSCLC cell growth in vitro and in vivo. Both c-myc and miR-150 were 
significantly over-expressed in NSCLC, while EPG5 was down-regulated in NSCLC. Expression 
levels of these molecules were well correlated, and also well correlated with patient survival.  
Conclusions: Our findings suggest that c-myc/miR-150/EPG5 mediated dysfunction of autophagy 
contributes to NSCLC development, which may provide a potential new diagnostic and therapeutic 
target in NSCLC. 
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Introduction 
Lung cancer is the most commonly diagnosed 
cancer and the leading cause of cancer mortality 
worldwide [1]. As the most frequently diagnosed 
pathological subtype, non-small cell lung cancer 
(NSCLC) counts for nearly 80% of all lung cancer 
cases [2]. Despite continuous development of novel 
therapeutic methods, the overall 5-year survival rates 
vary from 4-17% depending on the stage and regional 
differences [3]. Further understanding of molecular 
mechanisms associated with NSCLC progression is 
urgently needed in order to develop novel and 
effective therapeutic strategies. 
Macroautophagy (autophagy) has been reported 
as an important regulatory mechanism for 
tumorigenesis and progression of a variety of cancers, 
including NSCLC [4, 5]. Autophagy is a process of 
metabolic degradation at the cellular level, in which 
protein aggregates and defective organelles of the 
cytosol are sequestered by double-membrane 
autophagosomes, and then further fused with 
lysosomes for degradation [6]. This complex process 
is fine-tuned by several mediators [7, 8]. Upon the 
formation of autophagosome, the p62 protein act as a 
selective autophagy receptor for degradation of 
ubiquitinated substrates, which directly interacts with 
LC3 [9]. Consequently, the LC3 is cleaved by 
autophagy-related protein 4 (ATG4) to form cellular 
LC3I, that further covalently conjugated to 
phosphatidylethanolamine on the phagophore 
membrane to form LC3II, and finally both p62 and 
LC3II degraded by fusion with lysosome [10]. 
Therefore, impaired autophagy is accompanied by 
accumulation of p62, LC3II and ubiquitinated protein 
aggregates, and the level of p62 and LC3 combined 
with tandem fluorescent-tagged LC3 (ptf-LC3) has 
been used as markers for autophagic flux and the 
lysosomal fusion process [9, 11, 12]. Recently, EPG5 
gene has been reported to be essential for mediating 
the fusion of autophagosomes with late 
endosomes/lysosomes, in which EPG5 acts as a 
tethering factor through interaction with LC3 and 
Rab7 [13]. Previous study documented that recessive 
mutations in EPG5 gene cause a defective autophagy 
related human multisystem disorder Vici syndrome 
[14]. However, the role of EPG5 in NSCLC and the 
up-steam regulatory molecules of EPG5 remains 
unknown. 
Increasing evidences have been demonstrated 
that miRNAs play crucial roles in the regulation of 
autophagy process through balancing or modulating 
the expression of the autophagy-related targeting 
genes [15]. For instance, miR-30a can directly bind the 
3'-UTR of beclin1 and inhibits beclin1 expression to 
decrease autophagic activity in tumor cells [16]. 
miR-34a can impair autophagosome-lysosome fusion 
through repressing autophagy-related protein 9A 
(ATG9A) expression in cochlear cells [17]. In recent 
years, studies from us and others showed that 
miR-150 is over-expressed in NSCLC which 
significantly correlates the clinical TNM stages and 
poor prognosis [18, 19]. Interestingly, similar with 
miR-150, up-regulation of p62 and LC3 was detected 
in NSCLC tumor tissues from patients, and a 
combined high level of LC3 and p62 was significantly 
associated with aggressive tumor behavior and 
shorter survival of NSCLC [20, 21]. However, whether 
miR-150 regulates autophagy further contributes to 
NSCLC development is unknown. 
In this study, we demonstrate that miR-150 
inhibits autophagic flux, increases cellular ROS level 
and DNA damage, promotes NSCLC progression 
through repressing EPG5, which is shown to be a 
novel tumor suppressor in NSCLC by our evidence. 
Meanwhile, we found that c-myc increased the 
transcription and maturation of miR-150, and 
pharmacologically inhibition of c-myc inhibited 
NSCLC both in vitro and in vivo. Furthermore, the 
high expression of c-myc and miR-150 exhibited 
significant negative correlation with EPG5 in NSCLC 
patients. We concluded that c-myc/miR-150/EPG5 
axis-mediated dysfunction of autophagy contributed 
to NSCLC development, suggesting a potentially 
novel diagnostic and therapeutic target for NSCLC. 
Materials and Methods 
Human lung tissues and cell lines 
The human NSCLC tissues and non-neoplastic 
lung tissues were collected from the Xiangya Hospital 
of Central South University (ChangSha, China). This 
study was approved by the Ethics Committee of 
Xiangya Hospital. The human NSCLC cell lines 
(A549, H1299, H460, 95C, 95D) and human normal 
lung cell line (MRC-5) were purchased from the Cell 
Bank of Type Culture Collection of the Chinese 
Academy of Sciences, Shanghai Institute of Cell 
Biology. 
Plasmids and transfection 
pSUPER-miR-150 plasmid was constructed by 
our lab and the transfection experimental protocols 
were performed according to our previously 
published protocols [18]. The miR-150 inhibitor and 
the small interfering RNAs (siRNAs) targeting EPG5 
and negative control (siNC) were synthesized by 
GenePharma Co., Ltd (Shanghai, China). The 
chemically stabilized cholesterol-conjugated miR-150 
mimics (named as agomir-150) and miR-150 inhibitor 
(named as antagomir-150) and each control were 
obtained from RiboBio Co., Ltd. (Guangzhou, China). 
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The above-mentioned detailed sequences are shown 
in Table S1. For generation of stable cell lines, 
pSUPER-miR-150 and EPG5 shRNA-expressing 
plasmids or control vectors were transfected into 
NSCLC cells and screened for 3-4 weeks with 1 μg/ml 
puromycin after a 48 h transfection.  
RNA extraction and quantitative reverse 
transcription-PCR (qRT-PCR) 
mRNA or miRNA expression was measured by 
qRT-PCR analysis as previously described [18]. 
mRNA expression was normalized to GAPDH and 
miRNA was normalized to U6 snoRNA. The primers 
used for mRNAs and miRNA are listed in Table S1. 
Western blotting analysis  
Western blotting analysis was performed as we 
previously described [22]. Specific antibodies used 
were summarized in the Table S2. 
Transmission electron microscopy (TEM) 
Cells were fixed with 2.5% glutaraldehyde for 24 
h, post-fixed with 2% OsO4 for 2 h, followed by 
dehydration. Thin sections (50 nm) were cut on an 
Ultramicrotome (LKB-3 microtome, Sweden) and 
stained with uranyl acetate and lead citrate. Images 
were visualized by transmission electron microscope 
(HT7700, Japan). 
Immunofluorescence 
Cells were fixed with 4% paraformaldehyde 
solution for 15 min, washed three times with 
phosphate-buffered saline (PBS) and then 
permeabilized cells with 0.1% Triton X-100/PBS for 5 
min. The fixed preparations were blocked in 3% 
BSA/PBS for 1 h, incubated with primary antibodies 
for 1 h at room temperature, washed three times with 
PBS and then stained with fluorescence-conjugated 
secondary antibody (Invitrogen, Carlsbad, MA, USA). 
Specific antibodies used were summarized in the 
Table S2. Fluorescent images were acquired by the 
Leica SP5 II scanning confocal microscope (Leica, 
Bannockburn, USA). 
Quantitative LC3 puncta analyses 
Pri-miR-150 and mCherry-GFP-LC3 were 
co-transfected into cells for 48 h. Nutrient starvation 
was induced by treating cells with HBSS for 4 h. 
Fluorescent images of mCherry-GFP-LC3 were 
acquired by the Leica SP5 II scanning confocal 
microscope (Leica, Bannockburn, USA). 
Dual luciferase reporter assay 
The human EPG5 wild type or mutated 3'-UTR 
sequence containing the miR-150 binding site was 
cloned into the psiCHECK-2 vector. The primer 
sequences are listed in Table S1. Cells were seeded 
into 24-well plates and co-transfected with 
pri-miR-150 or control vector and wild-type or 
mutated EPG5 3'-UTR using Lipofectamine 3000. Both 
firefly and Renilla luciferase activities were measured 
after the 48 h transfection using the Dual-Luciferase 
Reporter 1000 Assay System (Promega, WI, USA) and 
were detected by the GloMax TM 20/20 detection 
system (E5331, Promega, WI, USA) according to the 
manufacturer’s instructions. Luciferase activities were 
normalized to Renilla luciferase.  
MTT assay 
Transient or stable transfected cells (3,000/well) 
were seeded in 96-well plates and grown for 1, 2, 3, 4 
or 5 days. Subsequently, 20 µl of MTT working 
solution was added to the medium and incubated for 
4 h after which the medium was removed, and 200 µl 
of dimethyl sulfoxide was added to dissolve the 
formazan crystals. The absorbance at 570 nm (A570) 
was measured on a microplate reader (BioRad, 
Hercules, USA).  
Colony formation assays 
Cells (1000/well) were seeded in 6-well culture 
plates and each group had 3 wells. After incubation 
for 14 days at 37℃, colonies were washed three times 
with PBS and stained with crystal violet solution. The 
colonies composed of more than 50 cells in a well 
were counted under a microscope.  
Determination of ROS 
Transfected cells were disassociated by 
trypsinization, washed by DPBS and suspended in 
HBSS with 10 μM of H2DCFDA (Invitrogen, 
Carlsbad, MA, USA) for incubating 15 minutes at 
37°C. Fluorescence was detected by flow cytometry. 
In vivo tumorigenesis in nude mice 
In vivo experiments were approved by the 
Animal Care and Use Committee of the third Xiangya 
Hospital of Central South University (Changsha, 
Hunan, China). All mice (BALB/C, nu/nu) were 4-6 
weeks old, female, and purchased from the Shanghai 
Lab Animal Research Center (Shanghai, China). For 
tumorigenicity assays, 2×106 stably transfected with 
miR-150 or shEPG5 cells in 0.2 ml RPMI-1640 medium 
were injected subcutaneously into the right upper 
back of the mice. The tumor volume for each mice was 
measured every 3 days. Three weeks after the 
injections, tumor-bearing mice were sacrificed, and 
the size of the tumor was measured by caliper 
measurement. Each group had 4-6 mice. 
Treatment experiments in nude mice 
All mice (BALB/C, nu/nu) were 4-6 weeks old, 
female, and purchased from the Shanghai Lab Animal 
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Research Center (Shanghai, China). For treatment 
with miR-150 agomir or antagomir, 2×106 stably 
transfected with shEPG5 or shNC cells were injected 
subcutaneously into the right upper back of the mice. 
Xenograft tumors were allowed to grow for 4 days 
and then the animals were divided into four groups. 
Mice were tail intravenous injected with agomir or 
antagomir and their control reagent every 4 days, 
respectively. The tumor volume for each mouse was 
measured every 3 days. 20 days after the injections, 
tumor-bearing mice were sacrificed, and the size of 
the tumor was measured by caliper measurement. For 
treatment with 10058-F4, AZD5153 or DMSO, 2×106 
A549 cells were injected subcutaneously into the right 
upper back of the mice. Tumors were allowed to grow 
for 3 days and then the animals were divided into 
three groups for therapy testing. Mice were 
intraperitoneal injected with 10058-F4 (20mg/kg), 
AZD5153 (10mg/kg) or DMSO every 3 days, 
respectively. The tumor volume for each mouse was 
measured every 3 days. 20 days after the injections, 
tumor-bearing mice were sacrificed, and the size of 
the tumor was measured by caliper measurement.  
Chromatin Immunoprecipitation 
Chromatin Immunoprecipitation (ChIP) assay 
was performed with Pierce™ Magnetic ChIP Kit 
(Thermo Fisher Scientific, Waltham, MA, USA) 
following the manufacturer’s protocol with some 
modifications. Briefly, cell suspensions were 
crosslinked with a final concentration of 1% 
formaldehyde. Chromatin was isolated, digested by 
mung bean nuclease (MNase), sheared by sonication, 
and immunoprecipitated with antibodies. 
Immunoprecipitated DNA was washed and eluted 
according to the manufacturer’s instructions. Eluted 
DNA and sheared input material were analyzed by 
qRT-PCR. 
Immunohistochemical staining 
Paraffin sections prepared from clinical NSCLC 
tumor or adjacent tissues were used for 
immunohistochemistry assays to detect protein 
expression levels of c-myc, p62, LC3, γ-H2AX or EPG5 
proteins. The indirect streptavidin-peroxidase method 
was used according to the manufacturer’s 
introduction. The antibodies used were summarized 
in the Table S2. 
Statistical analyses 
All statistical analyses were performed using 
SPSS 16.0 statistical software. Student's t-test was 
used to determine the significance of the differences 
between the control and the experimental groups. A 
two-sided p<0.05 was considered statistically 
significant. 
Results 
miR-150 inhibited the fusion of 
autophagosomes with lysosomes in NSCLC.  
To investigate the role of miR-150 in regulating 
the autophagy flux, we transfected miR-150 into 
NSCLC cells (A549, H460 and H1299). Under the 
electron microscope, large numbers of 
autophagosomes and less autolysosomes were 
observed in miR-150 overexpressed cells, which were 
similar to the H1299 cells treated with bafilomycin A1 
(Baf A1) (Figure 1A-B, Figure S1A), a lysosome 
inhibitor, that is used to evaluate autophagic flux [23]. 
Meanwhile, we examined the expression of p62, LC3 
and ubiquitinated protein aggregates (marked as UB), 
and found that overexpression of miR-150 increased 
the protein level of p62, LC3II and ubiquitinated 
protein aggregates. These miR-150 overexpression- 
enhanced effects were inhibited by Baf A1, but not by 
proteasome inhibitor MG132 (Figure 1C, Figure S1B), 
suggesting that miR-150 interfered with the substrate 
clearance by compromising autophagy/lysosome 
pathway rather than ubiquitin-proteasome system 
(UPS). In order to examine whether the increased p62 
was due to an indirect transcriptional upregulation, 
we measured p62 transcript levels and found no 
significant changes between control and miR-150 
overexpressing cells (Figure S1C), suggesting that the 
p62 accumulation was not due to transcriptional 
up-regulation, but perhaps a perturbation in 
autophagic degradation. Furthermore, immunofluo-
rescence staining revealed that miR-150 
overexpressed and Baf A1 treated cells were greatly 
enriched with autophagosomes labeled by LC3, while 
the co-localization of LC3 and lysosome-associated 
membrane protein 1 (LAMP1) were obviously 
decreased (Figure 1D-E, Figure S1D). To further 
determine autophagic flux, OPTN (Optic 
neuropathy-inducing protein, Optineurin), a most 
recently identified selective autophagy substrate [24], 
was found to accumulate in miR-150-overexpressed 
cells, which was inhibited by Baf A1 (Figure S1E). 
Next, we used a mRFP-GFP-LC3 reporter construct to 
analyze the autophagosomes and autolysosomes 
fusion, which can distinguish autophagosomes 
(mCherry positive/GFP positive; yellow dots) from 
autolysosomes (mCherry positive/GFP negative; red 
dots) [11]. As shown in Figure 1F-G, 
miR-150-transfected A549 and H1299 cells showed a 
decrease number of autolysosomes and an increase 
number of autophgosomes. Taken together, our 
results suggested that miR-150 suppressed 
autophagic flux by inhibiting the fusion of 
autophagosomes with lysosomes. 
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Figure 1. miR-150 inhibited the fusion of autophagosomes with lysosomes in NSCLC. (A) Overexpressing miR-150 increased the number of autophagosomes 
(yellow array) and decreased the number of autolysosomes (red array) in A549 and H1299 cells. Data are representative images of TEMs of three independent assays. Scale bar, 
2 μm. (B) Quantification of autophagosomes and autolysosomes per cell are expressed as mean±SEM, n= ~20 to 40 cells per group, *p<0.05, **p<0.01. (C) A549 and H1299 cells 
transfected with miR-150 or control vector were treated with Baf A1 (100 nM) and MG132 (10 μM) for 4 h and indicated proteins were detected by western blotting. Images 
are representatives and bar graphs are quantified results of three independent experiments expressed as the mean±SEM, *p<0.05 compared to the control. (D) Colocalization 
of LC3 and LAMP1 was detected by immunofluorescence. Scale bar, 10 μm. Data are representatives of three independent assays. (E) The LC3 and LAMP1 colocalization 
coefficiency is expressed as mean±SEM, n= ~30 to 50 cells of three independent experiments. (F) A549 and H1299 cells were cotransfected with miR-150 or control vector and 
mRFP-GFP-LC3. After 48 h, the cells were cultured with HBSS for 4 h and the autophagy flux was detected with scanning confocal microscope. Data are schematic drawing of 
the autophagy process (upper) and representative microscopy images of three independent assays showing red-coloured autophagolysosomes or yellow-coloured 
autophagosomes (lower). Scale bar, 10 mm. (G) Quantification of red, green and yellow puncta per cell are expressed as mean±SEM, n= ~20 to 40 cells. *p<0.05, **p<0.01. 
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miR-150 induced ER stress, ROS and DNA 
damage, and promoted NSCLC 
tumorigenesis. 
Previous studies have shown that 
autophagy-defective tumor cells preferentially 
accumulate ER chaperones, ROS, and damaged DNA 
lesions [25, 26]. We observed an elevated level of ER 
stress-activating related proteins Bip, p-eIF2α, ATF4 
and CHOP in miR-150 overexpressed A549 and 
H1299 cells (Figure 2A), suggesting that 
miR-150-mediated autophagy defects induced ER 
stress. Since autophagy deficiency causes 
accumulation of damaged mitochondria and induces 
the oxidative protein folding machinery, ROS levels 
were examined following miR-150 overexpression. As 
shown in Figure 2B, A549 and H1299 cells transfected 
with miR-150 displayed an increase in the ROS level 
compared to the control cells. Furthermore, immuno- 
fluorescence revealed that overexpression of miR-150 
induced distinct γ-H2AX foci formation in cells 
(Figure 2C-D). In addition, western blotting showed 
that overexpression of miR-150 markedly increased 
the accumulation of endonuclear γ-H2AX (Figure 2E), 
suggesting that miR-150 increased the DNA damage 
of NSCLC cells. More importantly, the oncogenic 
effect of miR-150 was evident by in vitro assay and the 
ability to enhance tumorigenesis was observed in vivo. 
Overexpression of miR-150 enhanced the proliferation 
of A549, H1299 and H460 cells in vitro as evaluated 
through MTT and plate colony formation assay 
(Figure 2F-G, Figure S2A-B). On the other hand, 
subcutaneous tumors from the H460 cells stably 
overexpressing miR-150 grew faster and had larger 
tumor volumes than those from the control group 
(Figure 2H, Figure S2C). In addition, deficient 
autophagic flux was further confirmed in the miR-150 
over-expressed mice tumors (Figure 2I). Collectively, 
our results suggested that overexpression of miR-150 
induced autophagy deficiency and accumulation of 
ER stress, ROS and DNA damage, and promoted the 
NSCLC tumorigenesis.  
EPG5 was a novel target for miR-150. 
To gain insight into the molecular mechanisms 
by which miR-150 inhibits autophagic flux, 
TargetScan bioinformatic method was performed to 
predict the putative targets of miR-150. Among the 
targets, autophagy-related genes were of particular 
interest. A preliminary screening identified EPG5 as a 
potential miR-150 target (Figure 3A), as EPG5 
harbored a miR-150 binding site and was reported to 
act as a tethering factor mediating the fusion of 
autophagosomes with lysosomes [13]. To validate 
whether EPG5 is a target gene for miR-150, we 
generated wild-type (WT) luciferase reporter 
constructs that included the 3'-UTR of the EPG5 genes 
and mutant type (MUT) reporter constructs, which 
contained mutated binding sequences for miR-150 
(Figure 3A). Cells were co-transfected with miR-150 
and the 3'-UTR constructs to determine the impact of 
miR-150 to the 3'-UTR of the EPG5 gene. As shown in 
Figure 3B, compared with the cells transfected with 
the control vector, co-transfection with miR-150 
significantly decreased the luciferase activity from 
WT 3'-UTR construct, but not from MUT 3'-UTR 
construct. Furthermore, qRT-PCR and western 
blotting showed that overexpression of miR-150 
profoundly down-regulated EPG5 at mRNA and 
protein levels in NSCLC cells (Figure 3C-D), while 
inhibition of miR-150 by miR-150 inhibitor 
up-regulated the expression of EPG5 in NSCLC cells 
(Figure 3E). The overexpression and inhibition 
efficiency of miR-150 were evaluated by qRT-PCR 
(Figure S3A). Consistent with these in vitro results, 
miR-150 over-expressed tumors derived from mice 
also showed down-regulated EPG5 protein level 
(Figure S3B). Notably, while our previous study 
showed that miR-150 was over-expressed in NSCLC 
cell lines compared to the MRC-5 normal human lung 
cells [18], here, in contrast, we detected that EPG5 
protein and mRNA levels were significantly 
down-regulated in NSCLC cell lines (95C, 95D, 
H1299, H460 and A549) compared with MRC-5 cells 
(Figure 3F-G). In addition, exogenous overexpression 
of miR-150 showed more potent inhibitory effect on 
EPG5 protein level than other potential up-stream 
miRNAs of EPG5 (miR-9-5p, miR-19-3p, miR-23-3p, 
miR-30-5p, and miR-143-3p, predicted by TargetScan, 
Figure S3C). Hence, our results suggested EPG5 was a 
plausible target of miR-150. 
Silencing EPG5 inhibited autophagic flux and 
promoted cell growth in NSCLC.  
EPG5 is essential for autophagosome maturation 
[27], and our results showed its mRNA and protein 
levels were significantly down-regulated in NSCLC 
cell lines (Figure 3E-F), therefore we next examined 
the function of EPG5 on NSCLC cell autophagic flux 
and tumorigenesis. Firstly, we established two EPG5 
stably knockdown cell lines in A549 cells (named as 
EPG5-sh2 and EPG5-sh3) and a control cell line 
(named as EPG5-shNC) using two EPG5 short hairpin 
RNAs (shRNAs) and a control shRNA (Figure 4A, 
Figure S4). As shown in Figure 4A, western blotting 
revealed that silencing of EPG5 dramatically 
increased the accumulation of p62, LC3 and 
ubiquitinated protein aggregates. Meanwhile, 
immunofluorescence staining showed silencing of 
EPG5 led to a significant reduction of co-localization 
of LC3-labeled autophagosomes with LAMP1-labeled 
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lysosomes (Figure 4B-C). On the other hand, silencing 
of EPG5 significantly promoted cell proliferation and 
tumorigenesis in vitro and in vivo (Figure 4D-E). The 
volume (Figure S5A) and weight (Figure 4F) of 
EPG5-silenced tumors were markedly bigger 
compared with the tumors formed by control cells. Of 
note, the mice body weight was not significantly 
different in EPG5 silenced groups and control group 
(Figure S5B). Together, these results indicated a 
protective role of EPG5 against NSCLC progression. 
miR-150 inhibited the autophagic flux and 
promoted NSCLC tumorigenesis through 
repressing EPG5.  
To validate that EPG5 is a functional target of 
miR-150 and is responsible for inhibiting autophagic 
flux and inducing cell growth, EPG5 siRNA and 
miR-150 inhibitor were introduced alone or 
simultaneously into NSCLC cells. Inhibition of 
miR-150 by miR-150 inhibitor up-regulated 
endogenous EPG5 expression, and restored the effect 
 
 
Figure 2. miR-150 induced ER stress, ROS and DNA damage, and promoted NSCLC tumorigenesis. (A) A549 and H1299 cells transfected with miR-150 or 
control vector and ER stress-related proteins were detected by western blotting. Images are representatives and bar graphs are quantified results of three independent 
experiments expressed as the mean±SEM, *p<0.05 compared to the control. (B) A549 and H1299 cells transfected with miR-150 or control vector for 48 h, and the intracellular 
ROS levels were detected by flow cytometry. Data are quantified results of three independent experiments expressed as the mean±SEM, *p<0.05. (C, D) The representative 
images of immunofluorescence of γ-H2AX in A549 and H1299 cells transfected with miR-150 or control vector (C) and the γ-H2AX foci fluorescence intensity was expressed 
as mean±SEM, n= ~30 to 50 cells of three independent experiments (D). (E) The expression levels of endonuclear γ-H2AX in A549 and H1299 cells transfected with miR-con 
or miR-150 were determined by western blotting. (F) A549 and H1299 cells proliferation as measured by the MTT assay after transfected with miR-150 or control vector, data 
are quantified results of three independent experiments expressed as the mean±SEM, *p<0.05, **p<0.01. (G) A549 and H1299 cells clonality as measured by the plate clone 
formation assay after stably transfected with miR-150 or control vector. Images are representatives and bar graphs are quantified results of three independent experiments 
expressed as the mean±SEM, **p<0.01 compared to the control. (H) H460 cells stably transfected with miR-150 or control vector were injected subcutaneously into the upper 
backs of the BALB/c nude mice. Data are mean volumes ±SEM at indicated times (n=4 per group), **p<0.01. (I) The indicated autophagy-related proteins in xenograft tumors 
were detected by western blotting.  
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of EPG5 knockdown-induced accumulation of p62, 
LC3 and ubiquitinated protein aggregates (Figure 
5A). Concurrently, inhibition of miR-150 also reversed 
the autophagic flux-inhibiting effects mediated by 
EPG5 siRNA, as electron microscope screening 
revealed the increase number of autolysosomes and 
less autophagosomes following simultaneous 
depletion of EPG5 and miR-150 (Figure 5B-C). These 
results were further strengthened by the observation 
from immunofluorescence staining that showed 
increased co-localization of LC3 labeled 
autophagosome with LAMP1 labeled lysosome after 
the co-treatment compare to knockdown of EPG5 only 
(Figure 5D).  
On the other hand, miR-150/EPG5 regulation 
axis was tested as a potential NSCLC therapeutic 
target. Using antagomir-150, a chemically stabilized 
miR-150 inhibitor, markedly inhibited control cells; 
while silencing EPG5 attenuated the anti-tumor effect 
of antagomir-150 in shEPG5 cells in vitro (Figure 5E). 
Next, subcutaneous xenografts were established in 
the flanks of nude mice using EPG5-sh3 cells and 
EPG5-shNC cells. Tail intravenous injection with 
antagomir-150 significantly decreased the expression 
of miR-150 in tumors (Figure S5C), and effectively 
inhibited the growth of EPG5-shNC cells. However, 
the phenomenon of significant reduction of tumor 
weights (p=0.0071) by antagomir-150 was diminished 
in EPG5-sh3 cells (p=0.0923, Figure 5F, Figure S5D). 
On the contrary, tail intravenous injection of 
agomir-150, a chemically stabilized miR-150 mimic, 
dramatically increased miR-150 expression in tumors 
(Figure S5C), and notably promoted tumor growth in 
EPG5-shNC harboring mice without causing any 
change in EPG5-sh3 xenograft (Figure S5E-G). The 
mice body weight did not significantly differ among 
these experimental groups indicating no sign of 
toxicity for antagomir-150 and agomir-150 treatment 
(Figure 5G, Figure S5H). These results suggested a 
reciprocal role of miR-150 and EPG5 during NSLC 
development. 
C-myc promoted expression of miR-150 and 
NSCLC tumorigenesis and progression. 
In order to understand the underlying 
mechanism for abnormally high expression of 
miR-150 in NSCLC, we used a publicly available 
ChIP-Seq data from the UCSC Genome Browser 
(http://genome.ucsc.edu/index.html) to identify potential 
transcription factors that are important for miR-150 
biosynthesis. Proto-oncogene c-myc was identified as 
it could potentially bind to the upstream regulatory 
region of the miR-150 gene (Figure S6). Furthermore, 
we demonstrated that c-myc bound directly to the 
 
 
Figure 3. EPG5 was a novel target for miR-150. (A) Schematic illustration of the predicted miR-150 conserved binding site in EPG5 3'-UTR of wild-type EPG5 mRNA 
(EPG5-wt-3'-UTR), and a EPG5 mutant containing two mutated nucleotides in the 3'-UTR of EPG5 (EPG5-mut-3'-UTR). (B) Luciferase activity assays of the EPG5-wt-3'-UTR or 
EPG5-mut-3'-UTR reporter in H460, A549 and H1299 cells transfected with miR-150 or the control vector. Data are quantified results of three independent experiments 
expressed as the mean±SEM, **p<0.01, NSp>0.05. (C, D) The mRNA level (C) and protein level (D) of EPG5 in H460, A549 and H1299 cells transfected with the miR-con or 
miR-150 were measured by qRT-PCR and western blotting, respectively. GAPDH served as control. Images are representatives and bar graphs are quantified results of three 
independent experiments expressed as the mean±SEM, *p<0.05, **p<0.01. (E) The protein level of EPG5 in H460, A549 and H1299 cells transfected with the miR-150 inhibitor 
(miR-150-in) or inhibitor control (IN-ctrl) were measured by western blotting. GAPDH served as control. Data are representatives of three independent assays. (F, G) The 
protein level (F) and mRNA level (G) of EPG5 were measured in a human normal lung cell line MRC-5 and five different NSCLC cell lines (95C, 95D, H1299, H460 and A549) 
using qRT-PCR and western blotting, respectively. GAPDH served as control. All experiments were performed in triplicate, and data are expressed as the mean±SEM, *p<0.05, 
**p<0.01. 
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upstream region of the miR-150 locus through a 
chromatin immunoprecipitation (ChIP) assay (Figure 
S7). To determine any effect of c-myc on miR-150 
transcription and maturation in NSCLC, pri-miR-150 
(primary miRNA), pre-miR-150 (precursor miRNA) 
and miR-150 levels were measured in the 
c-myc-overexpressing cells. As shown in Figure 6A-B, 
the levels of miR-150 primary, precursor transcripts 
and mature miR-150 were all increased 2-5 folds when 
A549 and H1299 cells were transfected with 
pENTER-c-myc plasmid.  
Considering the oncogenic roles of miR-150 in 
NSCLC and the role of c-myc in miR-150 regulation, 
we hypothesized that pharmacological inhibition of 
the expression and/or transcriptional activity of 
c-myc may be a promising anti-NSCLC therapeutic 
method. Therefore, we employed c-Myc and BRD4 
(Bromodomain-containing protein 4, which 
transcriptional activates c-myc [28]) inhibitors 
(10058-F4 [29] and AZD5153 [28]). As shown in the 
results, the level of c-myc in A549 and H1299 cells 
were dose dependently decreased when treated with 
c-Myc inhibitor 10058-F4 or BRD4 inhibitor AZD5153 
(Figure 6C). These treatments also led to a 
concomitant decrease in the level of miR-150 (Figure 
6D) and increase in the level of EPG5, as well as 
disordered ER stress and DNA damage pathways 
(Figure S8). MTT assay and colony formation assay 
showed that both 10058-F4 and AZD5153 
dramatically inhibited cell survival and colony 
formation in vitro (Figure 6E-G). Furthermore, the in 
vivo xenografts experiment showed that compared to 
DMSO control group, the growth of xenograft tumor 
cells were significantly inhibited (Figure 6H), and the 
volume and weight of the tumors were markedly 
smaller after injecting 10058-F4 and AZD5153 (Figure 
S9A, Figure 6I). The mice weight did not change in the 
10058-F4 group but decreased slightly in AZD5153 
group when compared with the control group (Figure 
S9B). In addition, the western blotting and qRT-PCR 
results showed that both 10058-F4 and AZD5153 
effectively inhibited the expression of c-myc and 
miR-150 in mice tumor tissues (Figure 6J-K). Taken 
together, these results suggested that the c-myc 
promoted NSCLC tumor growth in vitro and in vivo, 
and pharmacological inhibition of c-myc/miR-150 
pathway would be a promising anti-cancer therapy 
for NSCLC. 
 
 
Figure 4. Silencing EPG5 inhibited autophagic flux and promoted cell growth in NSCLC. (A) A549 cells stably expressing EPG5-shRNA2 and EPG5-shRNA3 were 
generated, and the expression levels of EPG5, p62, LC3, UB and GAPDH in control and EPG5-silenced A549 cells were determined by western blotting. Data are representatives 
of three independent assays. (B) Colocalization of LC3 and LAMP1 was detected by immunofluorescence. Scale bar, 10 μm. Data are representatives of three independent assays. 
(C) The LC3 and LAMP1 colocalization coefficiency is expressed as mean±SEM, n= ~30 to 50 cells of three independent experiments. (D) Control and EPG5-silenced A549 
cells proliferation as measured by the MTT assay. Each bar represents the mean ±SEM of three independent experiments. *p<0.05, **p<0.01. (E) A549 cells expressing 
control-shRNA, EPG5-shRNA2 or EPG5-shRNA3 were injected subcutaneously into the right flank of the BALB/c nude mice. Data are mean volumes ±SEM at indicated times 
(n=6 per group). (F) Data are mean weight ±S.E.M of tumor weight. n=6 per group. *p<0.05, **p<0.01. 
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Figure 5. miR-150 inhibited the autophagic flux and promoted NSCLC tumorigenesis through repressing EPG5. (A) Western blotting analyses of EPG5, p62, 
LC3, UB and GAPDH expression in A549 and H1299 cells transfected with NC-inhibitor plus siNC, miR-150 inhibitor plus siNC, NC-inhibitor plus siNC or miR-150 inhibitor 
plus siEPG5. Images are representatives and bar graphs are quantified results of three independent experiments expressed as the mean±SEM, *p<0.05 compared to the control. 
(B) A549 and H1299 cells transfected with siNC, siEPG5 or siEPG5 plus miR-150 inhibitor, data are representative images of TEMs of three independent assays. Scale bar, 2 μm. 
(C) Quantification of autophagosomes (yellow array) and autolysosomes (red array) per cell are expressed as mean±SEM, n= ~20 to 40 cells per group, *p<0.05, **p<0.01. (D) 
Colocalization of LAMP1 and LC3 was detected by immunofluorescence in A549 and H1299 cells transfected with siNC, siEPG5 or siEPG5 plus miR-150 inhibitor. Scale bar, 10 
μm. Data are representatives of three assays. The LC3 and LAMP1 colocalization coefficiency is expressed as mean±SEM, n= ~30 to 50 cells of three independent 
experiments. (E) The proliferation of control and EPG5-silenced A549 cells treated with antagomir-150 were measured by the MTT assay. Each bar represents the mean ±SEM 
of three independent experiments. (F, G) A549 cells expressing control-shRNA or EPG5- shRNA3 were injected subcutaneously into the right flank of the BALB/c nude mice, 
and tail intravenous injection with antagomiR-150 or control. Data are mean weight ±SEM of tumour (F) and mice body (G). n=3 per group. *p<0.05, **p<0.01.  
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C-myc/miR-150/EPG5 axis determine 
prognosis and overall survival of NSCLC 
patients. 
To define the clinical relevance of our findings, 
we examined c-myc, miR-150 and EPG5 expression 
using qRT-PCR in human normal lung tissues (NP, 
n=30) and NSCLC biopsy tissues (NSCLC, n=54). 
Indeed, c-myc expression was significantly higher in 
NSCLC tissues than in NP tissues (Figure 7A). 
Meanwhile, the result from TCGA data set showed 
that the expression of c-myc was markedly higher in 
NSCLC primary solid tumor than solid normal tissue 
(Figure 7B). KM-plotter database showed that higher 
expression of c-myc was significantly associated with 
shorter survival (Figure 7C). miR-150 also 
significantly up-regulated in NSCLC tissues than in 
NP tissues as well as positively correlated with c-myc 
expression, with Pearson’s correlation coefficient of 
0.407, p<0.0001 (Figure 7D-E). However, EPG5 
expression was significantly lower in NSCLC as 
analyzed in our clinical samples and in TCGA data set 
(Figure 7F-G). Moreover, EPG5 levels showed 
significantly negative correlation with miR-150 
expression (r=-0.46, p<0.0001, Figure 7H). At the same 
time, lower level of EPG5 expression was significantly 
correlated with lower survival of lung cancer patients, 
which was analyzed in KM-plotter database (Figure 
7I).  
 
 
Figure 6. C-myc promoted expression of miR-150 and NSCLC tumorigenesis and progression. (A) A549 and H1299 cells transfected with pENTER-c-myc or 
control vector, c-myc and GAPDH were detected by western blotting. Images are representatives of three independent experiments. (B) The levels of pri-miR-150 (primary 
miRNA), pre-miR-150 and miR-150 were measured in the control or c-myc overexpressing A549 and H1299 cells by qRT-PCR. Each bar represents the mean ±SEM of three 
independent experiments. (C) A549 and H1299 cells treated with 10058-F4 and AZD5153 for 48 hours as indicated concentration and c-myc and GAPDH were detected by 
western blotting. Images are representatives of three independent experiments. (D) A549 and H1299 cells treated with 10058-F4 (left) and AZD5153 (right) for 48 hours as 
indicated concentration and miR-150 expression were detected by qRT-PCR, U6 serve as an internal control, each bar represents the mean±SEM of three independent 
experiments. (E, F) The proliferation of A549 and H1299 cells treated with 10058-F4 (E) and AZD5153 (F) for 48 hours (upper) and 72 hours (down) as indicated concentration 
measured by the MTT assay. Each bar represents the mean±SEM of three independent experiments. (G) The clonality of A549 and H1299 cells measured by the plate clone 
formation assay after treated with 10058-F4 and AZD5153 for 7 days. (H) A549 cells were injected subcutaneously into the right flank of the BALB/c nude mice, and 
intraperitoneal injection with 10058-F4 (20mg/kg), AZD5153 (10mg/kg) or DMSO. Data are mean volumes±SEM at indicated times, n=6 per group. (I) Data are mean 
weight±SEM of tumour. n=6 per group. (J) Proteins extracted from tumor tissues, and c-myc and GAPDH were detected by western blotting. Images are representatives of three 
independent experiments. (K) RNA extracted from tumor tissues, and miR-150 expression were detected by qRT-PCR, U6 serve as an internal control, each bar represents the 
mean ±SEM of three independent experiments.*p<0.05, **p<0.01.  
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Figure 7. Correlation of c-myc/miR-150/EPG5 and other key genes with NSCLC development in clinical patients. (A) Levels of c-myc were measured in human 
NSCLC tissues (NSCLC, n=54) and non-neoplastic lung tissues (NP, n=30) using qRT-PCR. (B) The expression of c-myc in NSCLC primary solid tumor and solid normal tissue 
in TCGA data set. (C) Kaplan-Meier survival analysis of overall survival of 3021 NSCLC patients on the basis of c-myc expression. Log-rank test was used to calculate P values. 
(D) Levels of miR-150 were measured in human NSCLC tissues (NSCLC, n=54) and non-neoplastic lung tissues (NP, n=30) using qRT-PCR. (E) Correlation between miR-150 
and c-myc was determined using Spearman coefficient analysis in indicated clinical samples (n=84). (F) Level of EPG5 was measured in human NSCLC tissues (NSCLC, n=54) and 
non-neoplastic lung tissues (NP, n=30) using qRT-PCR. (G) The expression of c-myc in NSCLC primary solid tumor and solid normal tissue in TCGA data set. (H) Correlation 
between miR-150 and EPG5 was determined using Spearman coefficient analysis in indicated clinical samples (n=84). (I) Kaplan-Meier survival analysis of overall survival of 1882 
NSCLC patients on the basis of EPG5 expression. Log-rank test was used to calculate P values. (J) Level of miR-150 was measured in 12 pairs of NSCLC tissues and adjacent 
tissues using qRT-PCR. (K) Expression of c-myc, EPG5, p62, LC3, γ-H2AX and GAPDH were measured in 12 pairs of NSCLC tissues and adjacent tissues by western blotting. 
 
In addition, we examined the expression of 
c-myc/miR-150/EPG5 axis related genes in 12 pairs of 
NSCLC tissues and adjacent tissues. As shown in 
Figure 7J, compared with the adjacent tissues, 
miR-150 was significantly up-regulated in NSCLC 
tissues. Western blotting (Figure 7K) and 
immunohistochemical staining (Figure S10) showed 
an obvious increase of c-myc, p62, LC3 and γ-H2AX 
levels, whereas EPG5 expression was lower in NSCLC 
tissues compared with the adjacent tissues. Taken 
together, these results supported that abnormally 
expressed c-myc/miR-150/EPG5 axis caused 
dysfunction of authophagy correlated with the 
NSCLC development. 
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Discussion  
The role of miR-150 in NSCLC is controversial 
[18, 30-32], and the precise functions and underlying 
molecular mechanisms of miR-150 in the context of 
NSCLC were not clearly defined. In this study, we 
indicated that miR-150 significantly over-expressed in 
NSCLC patient tissues, and over-expression of 
miR-150 promoted the proliferation of NSCLC cells in 
vitro and in vivo. Our data suggested that, upon 
transcriptional activation by c-myc, miR-150 inhibited 
autophagic flux by repressing EPG5 to induce NSCLC 
development. At the same time, treatment with 
2'-O-methyl-modified miRNA inhibitor 
(antagomiRNA) [33, 34] targeting miR-150 markedly 
inhibited the growth of NSCLC in vivo and in vitro. 
Thus, our results revealed a previously unknown 
oncogenic function of miR-150 in NSCLC by 
modulating autophagy and provided the evidence 
that c-myc/miR-150/EPG5 axis could be a potential 
therapeutic target in the clinical setting.  
Mounting evidences have supported that 
dysfunction of autophagy results in a variety of 
human diseases including cancers [35, 36]. Studies 
from us and others indicated that miR-150 and two 
key autophagy-relative genes, p62 and LC3 were 
up-regulated in NSCLC, and both significantly 
correlated with the tumor progression and poor 
prognosis [18, 21, 37]. Therefore, we subjected to 
explore whether the miR-150-regulated impaired 
autophagy further promots NSCLC development. 
Herein, our results showed that miR-150 apparently 
blocked the fusion of autophagosome and lysosome, 
and elevated the accumulation of LC3 and p62. 
Previous studies have shown that cells with defective 
autophagic apparatus accumulate damaged 
organelles, elevated ROS production and activated 
DNA damage response, and potentially primed cells 
for tumor development [38, 39]. As an adaptive 
response such as autophagy deficiency, cells 
up-regulate the expression of GRP78/BiP, a major ER 
chaperone [40]. The ER stress-activated protein kinase 
PERK phosphorylates the alpha subunit of eukaryotic 
initiation factor 2 (eIF2α) in stressed cells, which in 
turn further selectively increases translation of 
Activating Transcription Factor 4 (ATF4), resulting in 
the induction of the downstream gene CHOP [41]. As 
shown in our data, overexpression of miR-150 
dramatically elevated levels of Bip, p-eIF2α, ATF4 and 
CHOP, indicating that miR-150-mediated autophagy 
defects induce ER stress. Furthermore, overexpression 
of miR-150 increased cellular ROS levels and DNA 
damage response. Taken together, the accumulation 
of p62, ER stress, ROS and DNA damage resulting 
from miR-150-mediated autophagy defect may result 
in enhancement of mutations, genome instability and 
NSCLC tumorigenesis and progression. 
Subsequently, we investigated the underlying 
molecular mechanism of miR-150 and revealed that 
miR-150 blocks the fusion of autophagosome with 
lysosome by directly binding to the 3'-UTR of EPG5, 
an autophagosome maturation-related protein [13], 
and repressing its mRNA and protein expression. 
Interestingly, we found that EPG5 expression was 
significantly lower in NSCLC, and significantly 
negatively correlated with miR-150 expression. 
Furthermore, the expression of EPG5 was correlated 
with longer survival of lung cancer patients and 
silencing EPG5 significantly promoted NSCLC cells 
growth, and attenuated the pro-tumor growth effect 
of miR-150 in vitro and in vivo. Therefore, we defined 
EPG5 as a new functional target of miR-150 and as a 
novel NSCLC tumor-suppressor. 
Finally, we explored the molecular mechanism 
that why miR-150 up-regulated in NSCLC. Previous 
studies reported that transcription factor c-myc is an 
important regulator of miRNAs biosynthesis, 
including transcription and maturation [42]. C-myc 
could bind to the promoter region and activates or 
represses the transcript of miRNAs, such as miR-17, 
miR-9 or miR-34a and miR-26a [43]. Meanwhile, 
c-myc has been reported to play a critical role in 
malignant transformation and is the most frequently 
amplified oncogene in human cancers, including 
breast, colon and lung cancer [44]. In this study, we 
identified that c-myc directly bound to the upstream 
region of the miR-150 and as an upstream regulator 
for miR-150 gene transcription. Overexpression of 
c-myc promoted the transcription and maturation of 
miR-150 in NSCLC cells. Meanwhile, our results 
demonstrated that c-myc was significantly highly 
expressed in NSCLC and positively correlated with 
miR-150 expression, and both c-myc and miR-150 
significantly associated with shorter survival. 
Furthermore, pharmacological inhibition of c-myc 
significantly repressed the expression of miR-150 and 
the proliferation of NSCLC cells in vitro and in vivo. 
Considering the important roles of miR-150 in NSCLC 
tumorigenesis and development, potentially 
therapeutic use of chemically stabilized miR-150 
inhibitor will be a replacement therapy. However, 
limited by the high cost of chemical modification and 
“off target” effects of miRNA inhibitors, continuing 
development of small molecules, which act 
pharmacologically to inhibit the c-myc can be a 
efficient therapeutic strategy for NSCLC [45]. 
Taken together, in this study, we revealed that 
high expression of miR-150 notably inhibited the 
fusion of autophagosomes with lysosomes through 
repressing the expression of EPG5, which played a 
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tumor-suppressor role in NSCLC cells. C-myc acted 
as an upstream transcriptional regulator of miR-150 
and pharmacological or genetic inhibition of 
c-myc/miR-150 significantly inhibited NSCLC cell 
growth in vitro and tumor growth in vivo. Our study 
disclosed that c-myc/miR-150/EPG5 axis mediated 
dysfunction of autophagy induced the accumulation 
of ER stress, ROS and DNA damage, and promoted 
the development of NSCLC, which may provide an 
effective therapeutic target to treat NSCLC. 
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